laboratori corp america hold
laboratori corp america hold
laboratori corp america
bullish analyst day focus long-term growth strategi underscor strong
foothold core market opportun leverag diagnost clinic
databas across enterpris reiter ow rais pt
come togeth enterpris three year covanc acquisit
labcorp posit leverag collect power two busi
segment drive enterprise-wid growth address evolv need
consum payor present showcas case studi support
cost save trial sponsor fewer week final protocol
opportun associ leadership posit precis medicin
involv cdx project client
expand covanc offer reacceler top-line growth alongsid margin
focus covanc recent share gain enhanc suit offer
chiltern includ tool endpoint expertis high-growth
indic oncolog women health ophthalmolog real-tim
inform lab databas proprietari analyt tool
xceller endpoint pharmacu global specimen solut
demonstr track record improv client product segment margin
expand benefit product gain increas scale increment
million launchpad cost save
diagnost side value-bas care improv connect consum
complex test tailwind key invest custom partnership
increasingli critic creat sticki consum rapidli evolv
healthcar marketplac build initi walgreen hospit
partnership expans mobil phlebotomi web base autom check-
in see path labcorp deliv sustain volum growth
medium-term pama cut translat diagnost segment margin
contract session manag express confid
stabl margin trajectori
long-term growth opportun leverag capabl across enterpris
deliv valu base care consumer healthcar labcorp
laboratori corp america hold lh lh us
 distribut unit state america
unless otherwis note metric base modelwar
base consensu methodolog
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
take step harmon two busi use diagnost inform
improv connect patient consum stakehold drive share
gain covanc custom billion current backlog total
compon new tool embed trial meanwhil invest
companion diagnost precis medicin biomark posit
compani growth long-term align drug manufactur focu
invest technolog across busi drive effici
enhanc product intern standard system lower cost
extern custom shorten clinic trial timelin pharma
client streamlin patient experi clinic help payor
manag care provid physician identifi gap care
tidbit manag expect market volum growth bad
debt expens manag diagnost partial off-set pama headwind
share repurchas expect mirror
million level broadli distribut across focu integr larg
scale like hold
updat estim rais pt execut key near-
term labcorp updat estim reflect higher growth expect cro
segment diagnost volum acquisit normal
contribut guidanc around tax reform new account polici
model revenu vs
prior consensu
compar guidanc
million model ep
vs prior consensu
compar guidanc dcf deriv price
target base base case forecast wacc termin
growth rate impli price-to-earnings
dcf analysi use wacc perpetu growth rate
impli price-to-earnings bull case ep
impli price-to-earnings bull case ep
lab volum acceler organ volum growth
increment tuck-in price benefit test mix
labcorp retain exclus price concess pama
begin moder medicar price cut mitig pama price
headwind pama conclud covanc busi top-lin reach
growth integr chiltern acquisit termin growth rate
impli price-to-earnings base case ep
impli price-to-earnings base case ep
lab busi benefit volum increas modest price increas
test mix organ volum growth plu
tuck-in move contract lh lh
retain busi due physician sticki pama begin
current median medicar rate adjust test outsiz
price declin covanc top-lin growth normal follow integr
chiltern acquisit tax rate declin follow tax reform
partial off-set price concess termin growth rate
impli price-to-earnings bear case ep
impli price-to-earnings bear case ep
lab util slow yield organ volum growth
tuck-in price benefit less test mix lh lose
exclus contract lh retain busi pama
begin median medicar rate base current lab univers
definit chiltern acquisit underperform covanc struggl see top-
line growth tax rate declin follow tax reform partial off-set
price concess termin growth rate
lh second largest refer lab
compani matur industri
stabil util core
reimburs pressur expect
price headwind pama manag
increas patient respons high
headwind like continu face
provid divers potenti growth
outsid matur slow grow core
volum growth tailwind ep
price growth bp increas
price growth tailwind ep
bad debt expens increment
declin bad debt expens margin
accret ep
ccd sale growth bp increas
cvd revenu growth accret
strateg partnership larg pharma
acquisit segment
risk achiev price
reimburs pressur may greater
expect
covanc chiltern deal synergi
inform opinion research prepar co llc and/or and/or morgan
stanley mexico de bolsa de and/or canada limit use disclosur section includ morgan
stanley co llc mexico de bolsa de canada limit affili
necessari
import disclosur stock price chart equiti rate histori regard compani subject report pleas see morgan
stanley research disclosur websit www morganstanley com/researchdisclosur contact invest repres
research broadway attent research manag new york ny usa
valuat methodolog risk associ recommend rate price target referenc research report pleas contact client
support follow us/canada hong kong latin america london
singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
follow analyst herebi certifi view compani secur discuss report accur express
receiv receiv direct indirect compens exchang express specif recommend view report ricki
unless otherwis state individu list cover page report research analyst
morgan stanley research publish accord conflict manag polici avail
import us regulatori disclosur subject compani
